Process for the preparation of benzo(a)quinolizidine derivatives
    1.
    发明授权
    Process for the preparation of benzo(a)quinolizidine derivatives 失效
    苯并(a)喹嗪衍生物的制备方法

    公开(公告)号:US4102886A

    公开(公告)日:1978-07-25

    申请号:US624470

    申请日:1975-10-21

    CPC分类号: C07D491/14 C07D455/06

    摘要: A process for the preparation of a compound of the formula I or a salt thereof ##STR1## wherein R.sup.1 and R.sup.2 each represent hydrogen or a C.sub.1-4 alkoxy group, or together form a methylenedioxy group;R.sup.3, r.sup.4, r.sup.5 and R.sup.6 are the same or different and are hydrogen or a group of the formula --CH.sub.2 --(CH.sub.2).sub.n --R.sup.7 with the proviso that at least one of the members R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than hydrogen; R.sup.7 is carboxyl or a carboxylic acid derivative group;N = 0.1 or 2 which comprises reacting a compound of the formula II ##STR2## with an organic secondary amine and reacting the N-amine of the formula III ##STR3## thus obtained wherein R.sup.8 and R.sup.9 each represent a C.sub.1-5 alkyl group, or together with the adjacent nitrogen atom form a 5- or 6-membered heterocyclic ring which can contain a further heteroatom, with a compound of the formula IVch.sub.2 .dbd. ch -- (ch.sub.2).sub.n -- R.sup.10 (IV)wherein R.sup.10 is a cyano or alkoxycarbonyl group.

    摘要翻译: 一种制备式I化合物或其盐的方法,其中R 1和R 2各自代表氢或C 1-4烷氧基,或一起形成亚甲二氧基; R 3,R 4,R 5和R 6相同或不同,为氢或式-CH 2 - (CH 2)n -R 7的基团,条件是至少有一个R 3,R 4,R 5和R 6不是 氢; R7是羧基或羧酸衍生物基团; N = 0.1或2,其包含用有机仲胺反应式II化合物,并使由此得到的式III的N-胺反应,其中R 8和R 9各自表示C 1-5烷基, 或者与相邻的氮原子一起形成可以含有另外的杂原子的5或6元杂环与式IV的化合物CH2 = CH-(CH2)n-R10(IV),其中R10是氰基或 烷氧基羰基。

    Benzo(a)quinolizidine derivatives
    2.
    发明授权
    Benzo(a)quinolizidine derivatives 失效
    苯并(a)喹嗪啶衍生物

    公开(公告)号:US4342871A

    公开(公告)日:1982-08-03

    申请号:US744608

    申请日:1976-11-24

    CPC分类号: C07D491/14 C07D455/06

    摘要: An antiphlogistic compound of the formula (I) ##STR1## or a pharmaceutically effective salt thereof wherein R.sup.1 and R.sup.2 are hydrogen or C.sub.1-4 alkoxy or together form a methylenedioxy group;R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are hydrogen or a group of the formula --CH.sub.2 --(CH.sub.2).sub.n -R.sup.7 with the proviso that at least one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than hydrogen;R.sup.7 is a carboxylic group or a carboxylic acid derivative group; n=0, 1 or 2, provided that if R.sup.3, R.sup.4 and R.sup.5 are hydrogen and R.sup.7 in the group R.sup.6 is cyano or alkoxycarbonyl, and n=1, then R.sup.1 and R.sup.2 are hydrogen, C.sub.2-4 alkoxy, or together form a methylenedioxy group.

    摘要翻译: 式(I)的消炎化合物(I)或其药学上有效的盐,其中R 1和R 2是氢或C 1-4烷氧基或一起形成亚甲二氧基; R3,R4,R5和R6是氢或式-CH2-(CH2)n-R7的基团,条件是R3,R4,R5和R6中的至少一个不是氢; R7是羧基或羧酸衍生物基团; n = 0,1或2,条件是如果R3,R4和R5是氢,R6中的R7是氰基或烷氧基羰基,n = 1,则R1和R2是氢,C2-4烷氧基或一起形成 亚甲二氧基。

    Antiphlogistic and anticoagulant condensed pyrimidine derivatives
    4.
    发明授权
    Antiphlogistic and anticoagulant condensed pyrimidine derivatives 失效
    消炎和抗凝血嘧啶衍生物

    公开(公告)号:US4460771A

    公开(公告)日:1984-07-17

    申请号:US742464

    申请日:1976-11-17

    CPC分类号: C07D471/04

    摘要: New optionally racemic or optically active pyrimido(1,2a) heterocyclic compounds of the formula ##STR1## wherein m is 0, 1 or 2,n is 0, 1 or 2,R is an alkyl group containing one to six carbon atoms,R.sup.1 is hydrogen, alkyl containing one to six carbon atoms,R.sup.2 is hydrogen, alkyl containing one to six carbon atoms, optionally substituted amino, optionally substituted hydroxy, carboxy or a group derived from a carboxylic acid orR.sup.1 and R.sup.2 together form a --(CH.dbd.CH).sub.2 -- group attached to the two adjacent carbon atoms of the ring A and the broken line represents a chemical bond,R.sup.3 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted cycloalkyl, optionally substituted acyl or optionally substituted hydroxy,R.sup.4 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted cycloalkyl, optionally substituted acyl orR.sup.3 and R.sup.4 together with the nitrogen can form an optionally substituted five-, six- or seven-membered ring, which can contain a further heteroatom or heteroatoms,R.sup.5 is oxygen or an optionally substituted imino group are disclosed as well as a process for the preparation thereof.

    摘要翻译: 新的任选的外消旋或光学活性嘧啶(1,2a)杂环化合物,其中m为0,1或2,n为0,1或2,R为含有1至6个碳原子的烷基,R 1为 是氢,含有1至6个碳原子的烷基,R 2是氢,含1至6个碳原子的烷基,任选取代的氨基,任选取代的羟基,羧基或衍生自羧酸的基团或R 1和R 2一起形成 - (CH = CH)连接到环A的两个相邻碳原子上的2-基团,虚线表示化学键,R 3是氢,任选取代的烷基,任选取代的芳基,任选取代的芳烷基,任选取代的杂环,任选取代的环烷基, 任选取代的酰基或任选取代的羟基,R 4是氢,任选取代的烷基,任选取代的芳基,任选取代的芳烷基,任选取代的杂环,任选取代的环烷基,选择 可以将氮取代的酰基或R3和R4与氮一起形成任选取代的五元,六元或七元环,其可以含有另外的杂原子或杂原子,R5是氧或任选取代的亚氨基, 其制备方法。

    Condensed pyrimidines
    6.
    发明授权
    Condensed pyrimidines 失效
    浓缩嘧啶

    公开(公告)号:US4495189A

    公开(公告)日:1985-01-22

    申请号:US364753

    申请日:1982-04-02

    IPC分类号: C07D471/04 A61K31/505

    CPC分类号: C07D471/04

    摘要: New compounds of the following formula are disclosed:1,6-dimethyl-3-carbamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)-pyrimidine;1,6-dimethyl-3-(N-tertiary-butyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-(N-2-phenethyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-[N-(3,3-diphenyl-propyl)-carbamoyl]-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-(N-phenyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine; and1,6-dimethyl-3-(N-methyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine, as well as pharmaceutical compositions containing these compounds and a method of inhibiting thrombocyte aggregation in mammals employing a pharmaceutically effective amount of at least one of these compounds.

    摘要翻译: 公开了下式的新化合物:1,6-二甲基-3-氨基甲酰基-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a) - 吡啶亚胺; 1,6-二甲基-3-(N-叔丁基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶; 1,1-二甲基-3-(N-2-苯乙基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-哒嗪(1,2-a)嘧啶; 1,6-二甲基-3- [N-(3,3-二苯基 - 丙基) - 氨基甲酰基] -4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶 ; 1,6-二甲基-3-(N-苯基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶; 和1,6-二甲基-3-(N-甲基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶,以及含有这些的药物组合物 化合物和使用药学上有效量的这些化合物中的至少一种来抑制哺乳动物血小板聚集的方法。